Prepared for
Life Science Tools
Hero Finding
Multi-sourcing is now the standard purchasing strategy: the vast majority of labs use more than one consumables vendor and a strong majority use more than one instrument vendor.
The category has bifurcated. For standard reagents and general-purpose consumables, the majority of buyers say basic performance is sufficient and price is the leading differentiator. For specialized or advanced reagents, the vast majority require enhanced performance and price drops to a much smaller role. The commercial implication is that share is no longer won by being the single source. It is won by understanding which slot a given buyer is filling and competing for that slot specifically.
Vast majority
Use more than one consumables vendor
Vast majority
Require high performance for specialized reagents
Strong majority
Report increased instrument and consumables spend since 2023
Vast majority
Report increased molecular workflow budgets since 2023
Study Design
N=157 lab decision-makers across pharma/biotech, clinical/healthcare, academic, and government settings · cross-region sample · all confirmed users with purchasing authority over the relevant instrument and consumable categories.
The sample was built to represent the full purchasing population for the relevant instruments and consumables across organization types and budget tiers, with sufficient depth in pharma/biotech and clinical/healthcare to support significance testing on the segments that drive the largest absolute spend.
Sample segmentation
Pharma/biotech · 60
Academic · 55
Clinical/healthcare · 38
Government · 4
Interview guide · core topics
- Budget evolution since 2023 across molecular workflow categories
- Vendor evaluation criteria for the instrument and consumable categories under study, and what has changed since 2023
- Multi-vendor sourcing patterns and the drivers behind secondary supplier selection
- Performance expectations and price sensitivity for standard versus specialized reagents
- Application-based selling: where validated workflow and application data influence vendor selection
- Customer journey: information sources, role of digital and AI-powered tools, and gaps in current buying experience
- Macroeconomic and supply chain pressure on purchasing behavior, by region and organization type
- Automation adoption in molecular workflows and its effect on vendor selection criteria
Recruit criteria
- Lab decision-maker with significant authority for purchasing the relevant instruments and consumables
- Confirmed current user of the instrument and consumable categories under study
- Pharma/biotech, clinical/healthcare, academic, or government organization
- Multi-region location; signed confidentiality agreement
Key Findings
What the research surfaced for commercial strategy.
Six signals defined the commercial brief and the application-based selling roadmap.
Vast majority
Report increased molecular workflow budgets since 2023
Strong majority
Report increased instrument and consumables spend since 2023
Vast majority
Use more than one consumables vendor
Vast majority
Require high performance for specialized reagents
~⅖
Report a meaningful change in vendor evaluation approach since 2023
Top source
Scientific literature leads buyer information sources
01
Demand growth is broad: the vast majority of organizations grew their molecular workflow budgets since 2023, and the strong majority grew instrument and consumables spend.
Growth is concentrated in pharma/biotech and clinical/healthcare, both of which combine larger absolute budgets with stronger growth rates than academic peers. Academic institutions report smaller budgets and more frequently flat year-on-year spend. The category-level demand picture is healthy, and the near-term commercial priority is to capture incremental dollars rather than defend a shrinking pool.
02
Multi-sourcing is the default, not the exception: the vast majority of labs use more than one consumables vendor and the strong majority use more than one instrument vendor.
Most organizations intentionally avoid full consolidation with a single supplier. Secondary sourcing is driven by targeted advantages: better pricing, superior performance for specific applications, and supply reliability or lead-time mitigation. Share fragmentation is a strategic choice by buyers, and the commercial response is to compete for second-source slots with the same intent applied to primary slots.
03
Standard reagents and general-purpose consumables are treated as commoditized: the majority of buyers say basic performance is sufficient and a meaningful share name price as the key differentiator.
Once baseline performance is met, decisions default to price, availability, and ease of procurement. For standard reagents, supply chain reliability is the top vendor evaluation criterion, followed by technical support quality and workflow compatibility. Application-based selling has limited traction in this segment. The lever is operational reliability.
04
Specialized reagents operate under a different decision logic: the vast majority require enhanced performance and the vast majority of those rate application-specific validation as extremely or very influential.
For specialized or advanced reagents, including high-fidelity enzymes, hot-start, and multiplex chemistries, customer service, technical documentation, and application-specific validation all rise to top-influence levels. The shift from standard to specialized adds a meaningful percentage-point gap across these support-related criteria. Application-based selling materially changes win rates here.
05
Vendor evaluation has been stable for most: a slight majority report no change since 2023, but a meaningful share have shifted, concentrated in European healthcare labs and mid-budget organizations.
European participants reported materially higher change rates than peers in other regions, with European healthcare labs and European pharma/biotech showing the highest evaluation shifts. Mid-budget labs reported substantially higher change rates than the largest budget tiers. The drivers are technology and workflow evolution, with macroeconomic factors playing a smaller and uneven role.
06
The buying journey is hybrid: scientific literature, peer recommendations, and sales reps lead, with AI-powered tools small but rising.
The vast majority of participants rate information from external or independent sources as very or extremely important. Buyers most often seek technical specifications and performance validation data, real-world evidence and peer experience, and step-by-step protocols or application guidance. The implication for content strategy is to invest in third-party-credible technical content and validated protocols, not brand-led narrative alone.
“For standard items, I really feel they are all equivalent, so we might as well just go with the cheapest price. For specialized workflows, we rely on alternative vendors because they consistently offer higher-fidelity chemistries, which are non-negotiable for generating reliable results.”— Lab Director, Academic Research Institution
Crosstab · Vendor Evaluation Criteria by Use Context
Support-related criteria carry significantly greater influence for specialized reagents than for standard reagents: customer service, technical documentation, and contractual flexibility all show meaningful percentage-point gaps.
Top-2-box importance ratings for vendor evaluation criteria, standard versus specialized reagents. The gap between the two columns defines where application-based selling adds measurable commercial value and where it does not. Indexed to peak cell across both columns = 100.
| Specialized reagents (indexed) | Standard reagents (indexed) | |
|---|---|---|
| Lot-to-lot consistency / reproducibility | 100 | 97 |
| Workflow or protocol compatibility | 100 | 96 |
| Compliance with regulatory requirements | 98 | 94 |
| Instrument compatibility | 94 | 93 |
| Customer service or support | 89 | 74 |
| Technical documentation, validation, or protocol support | 88 | 74 |
| Application-specific validation, labeling, or approvals | 88 | 82 |
| Product availability and delivery reliability | 87 | 87 |
| Contractual agreements or preferred vendor arrangements | 81 | 68 |
| Available purchasing channels | 74 | 61 |
| Bundling or volume discount options | 71 | 80 |
N=157 lab decision-makersCustomer service gap: meaningful specialized vs standardTechnical documentation gap: meaningfulContractual flexibility gap: meaningfulIndexed · blinded values
Heat Map · Multi-Sourcing Drivers
Cost is the dominant multi-sourcing driver for general-purpose consumables, performance dominates for specialized reagents, and supply continuity plays a meaningful role across all categories.
Top driver intensity for choosing a secondary supplier, by consumable category. Hot cells indicate the dominant driver in each category. Indexed to peak cell = 100.
| Standard reagents/kits | Specialized reagents/kits | Other general-purpose consumables | |
|---|---|---|---|
| Cost / pricing advantage | 81 | 66 | 100 |
| Performance for specific applications | 98 | 100 | 84 |
| Supply reliability and lead-time mitigation | 74 | 41 | 100 |
| Specialized or unique product capability | 75 | 100 | 28 |
| Validated workflows and lock-in | n/a | 100 | n/a |
Voice of Customer
How lab decision-makers describe the buying logic.
Verbatims selected to represent the range of perspectives on commodity pricing, specialized performance, supply continuity, and the digital journey.
Commodity Logic · Standard Reagents
“Price and logistical reliability become overwhelmingly dominant over technical performance for these commoditized items. For standard reagents, we are looking for consistent supply, predictable pricing, and lot consistency. Beyond that, the technical differentiation is small.”
— Lab Director, Academic Research Institution
Specialized Logic · Application Performance
“We rely on alternative vendors because they consistently offer higher-fidelity chemistries and more innovative reagents, which are non-negotiable for generating reliable results in our most sensitive workflows.”
— Principal Scientist, Academic Research Institution
Supply Continuity · Risk Mitigation
“The reason is to ensure an uninterrupted supply in case of a primary supplier shortage, which has happened in the past. We need second or third suppliers to provide validated testing continuously if one supplier cannot provide specific reagents or samples.”
— Director of Clinical Operations, Clinical Diagnostics Lab
Macro Pressure · Cost Sensitivity
“It has mainly impacted our organization with increased costs for reagents and consumables, with longer or less predictable lead times. There is a greater emphasis on supply chain variability and vendor diversification rather than changes to core technologies or workflows.”
— Lab Manager, Clinical Genomics Lab
Application-Specific Workflow · Clinical
“Workflows benefit from a vendor's superior inhibition resistance for difficult sample types. Fast multiplexing capabilities for simultaneous detection of multiple targets in complex panels are what we need most.”
— Senior Scientist, Clinical Diagnostics Laboratory
Counter-intuitive
The commodity slice is not a problem to fix. It is a profile to serve.
The instinct from an incumbent position is to argue against commoditization: to invest in technical narrative, application support, and premium positioning across the full portfolio. The data argues for a different posture. For the majority of buyers, standard reagents and general-purpose consumables are commoditized by design, and price plus availability is the rational decision logic. Trying to re-differentiate that segment is expensive and unlikely to move share. The higher-leverage move is to operate two distinct go-to-market motions in parallel: a high-efficiency commodity motion that competes on price, channel breadth, and supply reliability, and an application-led motion for specialized reagents where customer service, technical documentation, and validated workflow data measurably shift evaluation. The mistake is treating either segment with the other segment's playbook.
Strategic Implications
Four commercial moves from the research.
What the commercial leadership team took into territory planning, content strategy, and product positioning, grounded in the segmentation and the application-based selling evidence.
01
Run two go-to-market motions in parallel: commodity efficiency and specialized application-based selling.
For standard reagents and general-purpose consumables, compete on price discipline, channel reach, supply reliability, and procurement ease. For specialized reagents, deploy application-led selling with technical documentation, validated workflow assets, and senior scientist-to-scientist engagement. The two motions need separate commercial KPIs and separate content investments.
02
Treat the second-source slot as a primary commercial target, not a fallback.
With the vast majority of labs using more than one consumables vendor and clear secondary-source patterns by primary instrument vendor, second-slot capture is a structural growth opportunity. Build named-account plays for competitor instrument customers where the platform already has a documented secondary footprint, and lead with supply continuity and application performance rather than full consolidation.
03
Invest content strategy against the buyer's actual information journey: technical specs, real-world validation, and protocol guidance.
The majority of buyers seek technical specifications and performance validation data; smaller cohorts seek real-world evidence and peer experience or step-by-step protocols. Scientific literature and peer recommendations outrank sales reps. The content roadmap should prioritize peer-reviewed publication, validated protocol libraries, and application notes over brand-led campaign content.
04
Prioritize commercial focus on European healthcare labs and mid-budget organizations where evaluation shifts are concentrated.
European healthcare labs and European pharma/biotech lead the market in active vendor reassessment, alongside mid-budget labs. These segments are where displacement and second-source capture are most achievable in the next 12 to 18 months and warrant disproportionate field and marketing investment.
Success criteria · 12 months
- Separate commercial KPIs and content lines for commodity versus specialized motions, in market within two quarters
- Named-account second-source plays launched against top competitor instrument bases
- Application-specific validation and protocol assets published for the top specialized reagent applications
- European healthcare and mid-budget segment field investment increased relative to baseline plan
Risk register
| Local and regional competitor encroachment in Europe | HIGH |
| Continued price compression in commodity segment | HIGH |
| Supply chain disruption affecting secondary-source perception | MED |
| AI-powered buyer tools shifting share before content strategy adapts | MED |